Teladoc Health (NYSE:TDOC) Given New $16.00 Price Target at JPMorgan Chase & Co.

Teladoc Health (NYSE:TDOCFree Report) had its target price trimmed by JPMorgan Chase & Co. from $19.00 to $16.00 in a report released on Tuesday, Benzinga reports. The firm currently has a neutral rating on the health services provider’s stock.

A number of other equities research analysts have also issued reports on TDOC. Stifel Nicolaus cut their price target on Teladoc Health from $21.00 to $16.00 and set a hold rating for the company in a research note on Friday, April 26th. Canaccord Genuity Group dropped their price objective on shares of Teladoc Health from $28.00 to $25.00 and set a buy rating for the company in a report on Friday, April 26th. Needham & Company LLC reissued a hold rating on shares of Teladoc Health in a report on Friday, April 26th. Piper Sandler dropped their price objective on shares of Teladoc Health from $30.00 to $25.00 and set an overweight rating for the company in a report on Wednesday, February 21st. Finally, Wells Fargo & Company dropped their price objective on shares of Teladoc Health from $17.00 to $15.00 and set an equal weight rating for the company in a report on Monday, April 29th. Thirteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $18.22.

Read Our Latest Stock Report on Teladoc Health

Teladoc Health Trading Down 3.9 %

NYSE:TDOC opened at $11.83 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.82 and a quick ratio of 3.74. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -8.39 and a beta of 0.97. Teladoc Health has a one year low of $11.78 and a one year high of $30.41. The business has a fifty day moving average price of $13.79 and a 200-day moving average price of $17.12.

Teladoc Health (NYSE:TDOCGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.90%. The business had revenue of $646.13 million during the quarter, compared to analysts’ expectations of $637.31 million. During the same quarter in the previous year, the company posted ($0.37) EPS. The company’s quarterly revenue was up 2.7% on a year-over-year basis. Sell-side analysts forecast that Teladoc Health will post -1.04 EPS for the current year.

Insiders Place Their Bets

In other Teladoc Health news, CTO Nikolaos P. Nanis sold 2,866 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $41,614.32. Following the completion of the sale, the chief technology officer now owns 69,850 shares of the company’s stock, valued at $1,014,222. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Teladoc Health news, CTO Nikolaos P. Nanis sold 2,866 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $41,614.32. Following the completion of the sale, the chief technology officer now owns 69,850 shares of the company’s stock, valued at $1,014,222. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Trencher sold 6,780 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $98,445.60. Following the transaction, the insider now directly owns 28,192 shares in the company, valued at $409,347.84. The disclosure for this sale can be found here. Insiders sold a total of 137,368 shares of company stock valued at $1,968,587 over the last 90 days. Insiders own 0.95% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Institutional investors have recently modified their holdings of the stock. ICA Group Wealth Management LLC purchased a new position in shares of Teladoc Health during the fourth quarter worth approximately $28,000. Hexagon Capital Partners LLC increased its holdings in Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after buying an additional 1,065 shares during the period. RIA Advisory Group LLC purchased a new position in Teladoc Health during the fourth quarter valued at approximately $36,000. GAMMA Investing LLC purchased a new position in Teladoc Health during the fourth quarter valued at approximately $41,000. Finally, Principal Securities Inc. purchased a new position in Teladoc Health during the fourth quarter valued at approximately $45,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Featured Articles

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.